Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI Uniform resource identifier for web resources.
Authors
Li L, Ye J
Journal
Medicine
Year
2020
Hepatocellular carcinoma (HCC) is one of the most common neoplasms encountered, and its incidence is increasing worldwide. In this study, we explored the characteristics of gut microbiota in patients with primary hepatocellular carcinoma in advanced stage who received immune checkpoint inhibitors (ICIs) based on a large population with hepatitis B virus infection. An initial cohort of 65 patients with metastatic melanoma were included in this study. All patients were treated with ICIs at Fujian provincial geriatric hospital between August 2016 and June 2018. The 16S rDNA V4 region was amplified by Polymerase chain reaction and sequenced on the MiSeq platform. We found that the diversities of the gut microbiota in HCC who received ICIs were obviously increased. Negative feedback, which is controlled by interplay between microbial metabolic activities and host pathways, is thought to promote high bacterial diversity. We focused on the Faecalibacterium genus in response group, and Bacteroidales order in non-response group, and stratified patients into high versus low categories based on the median relative abundance of these taxa in the gut microbiome. Patients with high Faecalibacterium abundance had a significantly prolonged PFS versus those with a low abundance. Conversely, patients with a high abundance of Bacteroidales had a shortened progressive free survival compared to those with a low abundance. In summary, the present study examined the oral and gut microbiome of HCC patients undergoing immune checkpoint inhibitors immunotherapy. Significant differences were observed in the diversity and composition of the patient gut microbiome of responders versus non-responders.
Experiment 1
Needs review Marked as Needs review by Fatima on 2023-3-30
Curated date: 2022/07/15
Curator: Sharmilac
Revision editor(s): Sharmilac, Fatima, LGeistlinger, WikiWorks
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled (if applicable)
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Buccal mucosa , Feces Buccal mucosa,Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- hepatocellular carcinoma adult hepatoma,adult primary hepatocellular carcinoma,cancer, hepatocellular,carcinoma of liver,carcinoma of liver cells,carcinoma of the liver cells,carcinoma, hepatocellular, malignant,HCC,hepatoblastoma,hepatoblastoma caused by somatic mutation,hepatocellular adenocarcinoma,hepatocellular cancer,hepatocellular carcinoma,hepatoma,liver and intrahepatic bile duct carcinoma,liver cancer,liver carcinoma,liver cell cancer (hepatocellular carcinoma),liver cell carcinoma,primary carcinoma of liver cells,primary carcinoma of the liver cells
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Non-responders
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Responders
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients who were diagnosed with uveal HCC or who received ICIs in combination with targeted agents or with adoptive T cell transfer therapy
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
Signature 1
Reviewed Marked as Reviewed by Fatima on 2022/08/17
Source: Figure 1b
Description: Compositional differences in the gut microbiome are associated with responses to anti-PD-1 immunotherapy.
Abundance in Group 1: increased abundance in Responders
Signature 2
Reviewed Marked as Reviewed by Fatima on 2022/08/17
Source: Figure 1b
Description: Compositional differences in the gut microbiome are associated with responses to anti-PD-1 immunotherapy.
Abundance in Group 1: decreased abundance in Responders
| NCBI | Links |
|---|---|
| Bacteroidales | |
| Bacteroidota | |
| Bacteroidia | |
| Collinsella stercoris | |
| Bacteroides mediterraneensis | |
| Oleidesulfovibrio alaskensis | |
| Prevotella histicola | |
| Gardnerella vaginalis ⚠ | |
| Gardnerella ⚠ |
Signature 4
Source: Figure 1
Description: Compositional differences in the gut microbiome are associated with responses to anti-PD-1 immunotherapy.
Abundance in Group 1: increased abundance in Responders
Revision editor(s): Sharmilac
Retrieved from "https://bugsigdb.org/w/index.php?title=Study_667&oldid=100144"
Hidden category:
